Division of Pediatric Gastroenterology, Hepatology and Nutrition, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Division of Pediatric Gastroenterology, Hepatology and Nutrition, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Pancreatology. 2021 Jan;21(1):98-102. doi: 10.1016/j.pan.2020.12.010. Epub 2020 Dec 14.
Pancreatic ascites (PA) and pleural effusion (PPE) are rarely encountered in children. They develop due to disruption of the pancreatic duct (PD) or leakage from an associated pancreatic fluid collection (PFC). The literature on childhood PA/PPE and its management is scarce.
A retrospective review of children with PA/PPE diagnosed and managed at our center over the last 4 years was performed. The clinical, biochemical, radiological and management profiles were analyzed. Conservative management included nil per oral, octreotide and drainage using either percutaneous catheter or repeated paracentesis. Endotherapy included endoscopic retrograde cholangiopancreatography (ERCP) and transpapillary stenting.
Of the 214 children with pancreatitis, 15 (7%) had PA/PPE. Median age was 9 years with a third under 2 years. Median ascitic fluid amylase was 8840 U/L and all had elevated protein (>2.5 g/dl) and low serum ascites-albumin gradient ascites (<1.1). While PA/PPE was the first manifestation of underlying chronic pancreatitis (CP) in 10 children (67%), trauma was seen in 4 (26%) and hypertriglyceridemia in 1 (7%). On imaging, PD disruption could be identified in 10 (67%) children. ERCP and stenting was done in 10 children. Conservative management alone (n = 4) and endotherapy (n = 10) was successful in 93% with only one requiring surgery. The younger children (n = 4), were managed conservatively and only 1 of them required surgery. Resolution of PA/PPE was achieved in all with no recurrences.
Conservative management and ERCP plus transpapillary stenting results in resolution of majority of pediatric PA/PPE. Children presenting with PA/PPE needs to be evaluated for CP.
胰腺腹水(PA)和胸腔积液(PPE)在儿童中很少见。它们是由于胰管(PD)破裂或相关胰液积聚(PFC)漏出引起的。关于儿童 PA/PPE 及其治疗的文献很少。
对过去 4 年来在我院诊断和治疗的儿童 PA/PPE 患者进行回顾性分析。分析其临床、生化、影像学和治疗情况。保守治疗包括禁食、奥曲肽和经皮导管引流或反复穿刺引流。内镜治疗包括内镜逆行胰胆管造影(ERCP)和经乳头支架置入术。
在 214 例胰腺炎患儿中,15 例(7%)出现 PA/PPE。中位年龄为 9 岁,1/3 患儿年龄小于 2 岁。腹水淀粉酶中位值为 8840 U/L,所有患儿的蛋白均升高(>2.5 g/dl),血清腹水白蛋白梯度降低(<1.1)。10 例患儿(67%)中 PA/PPE 是慢性胰腺炎(CP)的首发表现,4 例患儿(26%)有创伤,1 例患儿(7%)有高甘油三酯血症。10 例患儿(67%)的影像学检查可发现 PD 破裂。10 例患儿行 ERCP 和支架置入术。93%的患儿通过保守治疗(n=4)和内镜治疗(n=10)成功治愈,仅 1 例患儿需要手术。4 例年龄较小的患儿(n=4)接受保守治疗,仅 1 例需要手术。所有患儿的 PA/PPE 均得到缓解,无复发。
保守治疗和 ERCP 加经乳头支架置入术可使大多数儿童 PA/PPE 得到缓解。PA/PPE 患儿需评估 CP。